Ovid Therapeutics Faces Delisting Concerns
Ticker: OVID · Form: 8-K · Filed: 2025-02-13T00:00:00.000Z
Sentiment: bearish
Topics: delisting, compliance, regulatory-filing
TL;DR
Ovid Therapeutics might get delisted - big trouble ahead.
AI Summary
Ovid Therapeutics Inc. filed an 8-K on February 13, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest event reported was on February 10, 2025. The company is incorporated in Delaware and its principal executive offices are located in New York, NY.
Why It Matters
This filing indicates potential issues with Ovid Therapeutics' compliance with stock exchange listing requirements, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards is a significant negative event that can lead to severe consequences for the company and its shareholders.
Key Players & Entities
- Ovid Therapeutics Inc. (company) — Registrant
- February 10, 2025 (date) — Earliest event reported
- February 13, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of Incorporation
- New York, New York (location) — Principal Executive Offices
FAQ
What specific listing rule or standard has Ovid Therapeutics Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Ovid Therapeutics Inc. has failed to satisfy, only that a notice has been issued.
What is the earliest date of the event reported in this 8-K?
The earliest date of the event reported is February 10, 2025.
When was this 8-K form filed with the SEC?
This 8-K form was filed with the SEC on February 13, 2025.
In which state is Ovid Therapeutics Inc. incorporated?
Ovid Therapeutics Inc. is incorporated in Delaware.
What is the address of Ovid Therapeutics Inc.'s principal executive offices?
The address of Ovid Therapeutics Inc.'s principal executive offices is 441 Ninth Avenue, 14th Floor, New York, New York 10001.
Filing Stats: 875 words · 4 min read · ~3 pages · Grade level 13.8 · Accepted 2025-02-13 17:15:24
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share OVID The Nasdaq Stock Mar
- $1.00 — below the minimum closing bid price of $1.00 per share during the last 31 consecutiv
Filing Documents
- d385884d8k.htm (8-K) — 24KB
- 0001193125-25-026192.txt ( ) — 143KB
- ovid-20250210.xsd (EX-101.SCH) — 3KB
- ovid-20250210_lab.xml (EX-101.LAB) — 18KB
- ovid-20250210_pre.xml (EX-101.PRE) — 11KB
- d385884d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized Date: February 13, 2025 OVID THERAPEUTICS INC. By: /s/ Jeffrey Rona Name: Jeffrey Rona Title: Chief Business and Financial Officer